BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 9076381)

  • 1. Antithrombin III supplementation for patients undergoing PTCA for unstable angina pectoris. A controlled randomized double-blind pilot study.
    Grip L; Blombäck M; Egberg N; Olsson A; Svane B; Velander M
    Eur Heart J; 1997 Mar; 18(3):443-9. PubMed ID: 9076381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant hirudin as a periprocedural antithrombotic in coronary angioplasty for unstable angina pectoris.
    Hafner G; Rupprecht HJ; Luz M; Terres W; Schindel F; Friesen HJ; Heinrichs H; Jessel A; Meyer J; Prellwitz W
    Eur Heart J; 1996 Aug; 17(8):1207-15. PubMed ID: 8869862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjunctive intracoronary infusion of antithrombin III during percutaneous transluminal coronary angioplasty. Results of a prospective, randomized trial.
    Schächinger V; Allert M; Kasper W; Just H; Vach W; Zeiher AM
    Circulation; 1994 Nov; 90(5):2258-66. PubMed ID: 7955182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antithrombotic treatment (argatroban vs. heparin) in coronary angioplasty in angina pectoris: effects on inflammatory, hemostatic, and endothelium-derived parameters.
    Suzuki S; Matsuo T; Kobayashi H; Matsuo M; Shimamo C; Koide M; Sakamoto S
    Thromb Res; 2000 May; 98(4):269-79. PubMed ID: 10822073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes.
    Flather MD; Weitz JI; Yusuf S; Pogue J; Sussex B; Campeau J; Gill J; Schuld R; Joyner CD; Morris AL; Lai C; Théroux P; Marquis JF; Chan YK; Venkatesh G; Jessel A
    Eur Heart J; 2000 Sep; 21(17):1473-81. PubMed ID: 10952840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjunctive infusion of antithrombin III during percutaneous transluminal coronary angioplasty.
    Huber K; Maurer G
    Eur Heart J; 1997 Mar; 18(3):362-3. PubMed ID: 9076371
    [No Abstract]   [Full Text] [Related]  

  • 7. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris.
    Gold HK; Torres FW; Garabedian HD; Werner W; Jang IK; Khan A; Hagstrom JN; Yasuda T; Leinbach RC; Newell JB
    J Am Coll Cardiol; 1993 Apr; 21(5):1039-47. PubMed ID: 8459055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early Administration of Reviparin in a Double-Blind Unfractionated Heparin and Placebo-Controlled Evaluation.
    Karsch KR; Preisack MB; Baildon R; Eschenfelder V; Foley D; Garcia EJ; Kaltenbach M; Meisner C; Selbmann HK; Serruys PW; Shiu MF; Sujatta M; Bonan R
    J Am Coll Cardiol; 1996 Nov; 28(6):1437-43. PubMed ID: 8917255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of heparin therapy on percutaneous transluminal coronary angioplasty outcome in unstable angina pectoris.
    Laskey MA; Deutsch E; Barnathan E; Laskey WK
    Am J Cardiol; 1990 Jun; 65(22):1425-9. PubMed ID: 2353646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes of hemostasis, endogenous fibrinolysis, platelet activation and endothelins after percutaneous transluminal coronary angioplasty in patients with stable angina.
    Borries M; Heins M; Fischer Y; Stiegler H; Peters A; Reinauer H; Schoebel FC; Strauer BE; Leschke M
    J Am Coll Cardiol; 1999 Aug; 34(2):486-93. PubMed ID: 10440163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of recombinant hirudin (CGP 39 393) versus heparin in patients with stable angina undergoing coronary angioplasty.
    van den Bos AA; Deckers JW; Heyndrickx GR; Laarman GJ; Suryapranata H; Zijlstra F; Close P; Rijnierse JJ; Buller HR; Serruys PW
    Circulation; 1993 Nov; 88(5 Pt 1):2058-66. PubMed ID: 8222099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant hirudin (HBW 023) prevents troponin T release after coronary angioplasty in patients with unstable angina.
    Rupprecht HJ; Terres W; Ozbek C; Luz M; Jessel A; Hafner G; vom Dahl J; Kromer EP; Prellwitz W; Meyer J
    J Am Coll Cardiol; 1995 Dec; 26(7):1637-42. PubMed ID: 7594097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of prolonged intravenous heparin in unstable angina patients prior to coronary angioplasty.
    Gangasani SR; O'Neill WW; Grines CL
    J Interv Cardiol; 2001 Aug; 14(4):423-8. PubMed ID: 12053496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators.
    Serruys PW; Herrman JP; Simon R; Rutsch W; Bode C; Laarman GJ; van Dijk R; van den Bos AA; Umans VA; Fox KA
    N Engl J Med; 1995 Sep; 333(12):757-63. PubMed ID: 7643882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activated clotting times in acute coronary syndromes and percutaneous transluminal coronary angioplasty.
    Wilson JM; Dougherty KG; Ellis KO; Ferguson JJ
    Cathet Cardiovasc Diagn; 1995 Jan; 34(1):1-5. PubMed ID: 7728844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Failure of epoprostenol (prostacyclin, PGI2) to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty: results of a randomised placebo controlled trial.
    Gershlick AH; Spriggins D; Davies SW; Syndercombe Court YD; Timmins J; Timmis AD; Rothman MT; Layton C; Balcon R
    Br Heart J; 1994 Jan; 71(1):7-15. PubMed ID: 8297699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized trial comparing intravenous nitroglycerin and heparin for treatment of unstable angina secondary to restenosis after coronary artery angioplasty.
    Doucet S; Malekianpour M; Théroux P; Bilodeau L; Côté G; de Guise P; Dupuis J; Joyal M; Gosselin G; Tanguay JF; Juneau M; Harel F; Nattel S; Tardif JC; Lespérance J
    Circulation; 2000 Mar; 101(9):955-61. PubMed ID: 10704160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identifying patients at high risk for restenosis after percutaneous transluminal coronary angioplasty for unstable angina pectoris.
    Halon DA; Merdler A; Shefer A; Flugelman MY; Lewis BS
    Am J Cardiol; 1989 Aug; 64(5):289-93. PubMed ID: 2526992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Low molecular weight heparin, reviparin, after PTCA: results of a randomized double-blind, standard heparin and placebo controlled multicenter study (REDUCE Study].
    Preisack MB; Baildon R; Eschenfelder V; Foley D; Garcia E; Kaltenbach M; Meisner C; Selbmann HK; Serruys PW; Shiu MF; Sujatta M; Bonan R; Karsch KR
    Z Kardiol; 1997 Aug; 86(8):581-91. PubMed ID: 9417748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aggressive clinical pattern of angina at restenosis following coronary angioplasty in unstable angina.
    Foley JB; Chisholm RJ; Common AA; Langer A; Armstrong PW
    Am Heart J; 1992 Nov; 124(5):1174-80. PubMed ID: 1442483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.